MX2021015121A - Secuencias lider. - Google Patents

Secuencias lider.

Info

Publication number
MX2021015121A
MX2021015121A MX2021015121A MX2021015121A MX2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A
Authority
MX
Mexico
Prior art keywords
pvc
payload
effector
leader sequence
needle complex
Prior art date
Application number
MX2021015121A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas R Waterfield
Joseph Healey
Alexia Hapeshi
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Warwick filed Critical Univ Warwick
Publication of MX2021015121A publication Critical patent/MX2021015121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MX2021015121A 2019-06-07 2020-06-05 Secuencias lider. MX2021015121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908155.3A GB201908155D0 (en) 2019-06-07 2019-06-07 Leader sequence
PCT/GB2020/051380 WO2020245611A1 (en) 2019-06-07 2020-06-05 Leader sequence

Publications (1)

Publication Number Publication Date
MX2021015121A true MX2021015121A (es) 2022-03-17

Family

ID=67386182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015121A MX2021015121A (es) 2019-06-07 2020-06-05 Secuencias lider.

Country Status (12)

Country Link
US (1) US20230076614A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980545A1 (cg-RX-API-DMAC7.html)
JP (2) JP7748288B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220133757A (cg-RX-API-DMAC7.html)
CN (1) CN114008205A (cg-RX-API-DMAC7.html)
AU (1) AU2020288380B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024592A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142462A1 (cg-RX-API-DMAC7.html)
GB (1) GB201908155D0 (cg-RX-API-DMAC7.html)
MX (1) MX2021015121A (cg-RX-API-DMAC7.html)
SG (1) SG11202113297RA (cg-RX-API-DMAC7.html)
WO (1) WO2020245611A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554283A (zh) * 2022-01-29 2023-08-08 中国医学科学院病原生物学研究所 多肽注射系统及其用途
EP4479082A4 (en) 2022-02-15 2026-06-10 Broad Inst Inc CELL-TYPE SPECIFIC TARGETING CONTRACTILE INJECTION SYSTEM
EP4547848A1 (en) 2022-06-30 2025-05-07 Københavns Universitet Contractile injection system and use thereof
CN119735656A (zh) * 2023-09-22 2025-04-01 北京朝赛蕴生物科技有限公司 一种蛋白复合物的制备纯化及应用
GB202417349D0 (en) 2024-11-26 2025-01-08 Nanosyrinx Ltd Method of purification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US9951340B2 (en) * 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
RU2755282C2 (ru) * 2015-10-14 2021-09-14 Байер Кропсайенс Лп Ген ахм1554, кодирующий дельта-эндотоксин, и способы его применения

Also Published As

Publication number Publication date
CA3142462A1 (en) 2020-12-10
SG11202113297RA (en) 2021-12-30
JP7866663B2 (ja) 2026-05-27
AU2020288380B2 (en) 2026-07-09
BR112021024592A2 (pt) 2022-01-18
US20230076614A1 (en) 2023-03-09
EP3980545A1 (en) 2022-04-13
WO2020245611A1 (en) 2020-12-10
KR20220133757A (ko) 2022-10-05
JP7748288B2 (ja) 2025-10-02
CN114008205A (zh) 2022-02-01
JP2025114573A (ja) 2025-08-05
GB201908155D0 (en) 2019-07-24
JP2022535283A (ja) 2022-08-05
AU2020288380A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
BR112021024592A2 (pt) Sequência líder
ES3064150T3 (en) Anti-myostatin antibodies and methods of use
BR112021026376A2 (pt) Proteínas de fusão flt3l-fc e métodos de uso
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
CO2021017650A2 (es) Vectores víricos y uso de los mismos en terapias celulares adoptivas
MX2020013579A (es) Componentes cascada y complejos cascada producidos por ingenieria.
MX2019015940A (es) Compuestos que comprenden un enlazador escindible y sus usos.
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CL2020000606A1 (es) Sistema de expresión de paramyxoviridae.
CL2022000193A1 (es) Composición de vacuna y sus usos para el control o la prevención de una infestación por piojos de mar (divisional de la solicitud no. 201900422)
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
PT4219688T (pt) Células t invariantes associadas à mucosa (mait) que expressam recetores de antigénio quiméricos
CL2023001666A1 (es) Composiciones de los agentes de unión a antígenos de la guanilil ciclasa c (gcc) y sus métodos de uso
PY1965502A (es) Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos
MX2018003445A (es) Expresion de proteinas que contienen fc.
BR112018013381A2 (pt) anticorpo especificamente ligante a antígenos derivados de miobacteria ou fragmento ligante a antígeno do mesmo
BR112018001967A2 (pt) material de gravação sensível ao calor.
UY37407A (es) Promotores para vacunas de vectores ehv-1 y composiciones farmacéuticas que los contienen
AR108642A1 (es) Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos
CL2024000116A1 (es) Identificación de receptores y antígenos de células t específicos de tumores comunes
BR112015023119A2 (pt) proteína de fusão, sequência de ácido nucleico, cassete de expressão, célula, método para determinar se um composto teste é um composto inibidor de bromodomínio e kit
PY1965505A (es) Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos